Neither Arvinas nor Pfizer now wants vepdegestrant
So who else could be interested in the oestrogen degrader?
Astra and J&J tussle over first-line lung
The companies clash over survival curve similarities – and differences.
World Lung 2025 – crossing curves in lung cancer
Tolerability could decide first-line therapy in EGFRm disease.
The month ahead: September’s upcoming events
It’s a new term for biotech and its investors.
FDA doubles down on overall survival
New draft guidance could see the agency getting ever stricter.
Gilead gets into in vivo Car-T
Interius, one of the most advanced players, will cost $350m.
Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Astra’s Neogene investment nosedives
NT-125 is discontinued, while two key Datroway readouts are delayed.
Sino takes out the rest of Merck’s partner
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
